FEMSelect
The developer the FDA cleared and CE Marked system for suturing ligaments of the pelvic floor as an approach to minimally-invasive Pelvic Organ Prolapse (POP) procedures.
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 40 % | - | 29 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
FemSelect is a medical technology company specializing in a minimally invasive, meshless system for treating uterine prolapse. The company's core product, EnPlace, anchors sutures to the pelvic floor ligaments without the use of transvaginal mesh, thereby eliminating mesh-related complications. FemSelect primarily serves women suffering from pelvic organ prolapse, a condition affecting 30-50% of women during their lifetime. The market for this solution is expanding rapidly due to the aging population. The business model involves selling the EnPlace system to healthcare providers and hospitals, generating revenue through product sales and potentially through licensing agreements. The company emphasizes quick patient recovery, with most patients resuming normal activities within 2-3 days and avoiding overnight hospital stays.
Keywords: uterine prolapse, minimally invasive, meshless, pelvic floor, quick recovery, healthcare, women's health, surgical system, medical technology, EnPlace.